The table below shows AbCellera Biologics Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$131.29M
-$108.56M
-$43.88M
$277.36M
$244.58M
$22.69M
Capital expenditure
$42.77M
$78.40M
$76.95M
$70.66M
$58.45M
$9.67M
Investing cash flow
$87.75M
$121.41M
-$221.11M
-$352.63M
-$332.25M
-$119.78M
Dividends paid
-
-
-
-
-
ABCL operating cash flow (10-K history)
AbCellera Biologics Inc. reported operating cash flow of -$131.29M for fiscal year 2025. That is down 20.9% from -$108.56M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from $2.69M (FY 2019) to -$131.29M. Figures come from the company's audited annual reports as filed with the SEC.
